title: Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin.
abstract: We report a 13-year-old boy who developed dyspnea at rest 1 year after the occurrence of cGVHD following an allogeneic bone marrow transplant (BMT). Pulmonary function data, imaging studies, lung biopsy, and bronchoalveolar lavage were consistent with the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP). Although reports suggest that oral methylprednisolone or methylprednisolone pulse therapies improve BOOP after BMT, we treated our patient with a combination of oral prednisolone (1 mg/kg) and low dose erythromycin (10 mg/kg) to avoid the side-effects of high-dose steroids. With this therapy, our patient showed clinical and radiological improvements within 1 week. The steroids were tapered off 12 months later and erythromycin was given for 14 months. We conclude that therapy consisting of a combination of oral prednisolone and low-dose erythromycin for BOOP after BMT may minimize the dose and duration of steroid use.
authors.affiliation: Department of Pediatric Hematology-Oncology, Institute of Medical Science, The University of Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ishii
authors.forename: A
authors.initials: A
authors.lastname: Manabe
authors.forename: Y
authors.initials: Y
authors.lastname: Ebihara
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: H
authors.initials: H
authors.lastname: Yoshino
authors.forename: T
authors.initials: T
authors.lastname: Mitsui
authors.forename: H
authors.initials: H
authors.lastname: Hisakawa
authors.forename: H
authors.initials: H
authors.lastname: Yagasaki
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Yoshimasu
authors.forename: R
authors.initials: R
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: A
authors.initials: A
authors.lastname: Masunaga
authors.forename: K I
authors.initials: KI
authors.lastname: Sugita
authors.forename: T
authors.initials: T
authors.lastname: Nakahata
authors.forename: S
authors.initials: S
authors.lastname: Asano
authors.forename: K
authors.initials: K
authors.lastname: Tsuji
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018549:Cryptogenic Organizing Pneumonia / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000008:administration & dosage*; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage*; D014184:Transplantation, Homologous
chemical_list: D004917:Erythromycin; D011239:Prednisolone